Facebook
Twitter
YouTube
Instagram
    • español
    • English
  • Contacto
  • español 
    • español
    • English
  • Mi Cuenta
Acerca deAutoresTítulosTemasColeccionesComunidades☰
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ver ítem 
    xmlui.general.dspace_homeCentros e Institutos de InvestigaciónCICVyA. Centro de Investigación en Ciencias Veterinarias y AgronómicasInstituto de BiotecnologíaArtículos científicosxmlui.ArtifactBrowser.ItemViewer.trail
  • Inicio
  • Centros e Institutos de Investigación
  • CICVyA. Centro de Investigación en Ciencias Veterinarias y Agronómicas
  • Instituto de Biotecnología
  • Artículos científicos
  • Ver ítem

Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19

Resumen
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant [ver mas...]
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic. [Cerrar]
Thumbnail
Autor
Villafañe, Luciana María;   Gallo Vaulet, Maria Lucia;   Viere, Florencia M.;   Klepp, Laura Ines;   Forrellad, Marina Andrea;   Bigi, María Mercedes;   Romano, Maria Isabel;   Magistrelli, Giovanni;   Rodríguez Fermepin, Marcelo;   Bigi, Fabiana;  
Fuente
Journal of Immunological Methods 500 : 113182 (January 2022)
Fecha
2022-01
Editorial
Elsevier
ISSN
0022-1759
URI
http://hdl.handle.net/20.500.12123/10871
https://www.sciencedirect.com/science/article/pii/S0022175921002271
DOI
https://doi.org/10.1016/j.jim.2021.113182
Documentos Relacionados
Formato
pdf
Tipo de documento
artículo
Proyectos (ver más)

INTA/2019-PD-E5-I102-001/2019-PD-E5-I102-001/AR./Desarrollo de vacunas y tecnologías para mejorar las estrategias profilácticas y terapéuticas de las enfermedades que afectan la producción animal y la salud pública

Palabras Claves
COVID-19; Coronavirus del Síndrome Respiratorio Agudo Grave 2; Severe Acute Respiratory Syndrome Coronavirus 2; Diagnóstico; Diagnosis; ELISA; Técnicas Inmunológicas; Immunological Techniques; SARS-CoV-2;
Derechos de acceso
Embargado
Descargar
Compartir
  • Compartir
    Facebook Email Twitter Mendeley
Excepto donde se diga explicitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Metadatos
Mostrar el registro completo del ítem